LENZ Therapeutics, Inc.
LENZAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 19, 2026 | Piper Sandler | $5.00(+53%) | $3.27 | TheFly | |
| Aug 12, 2026 | Piper Sandler | $7.00(+34%) | $5.21 | TheFly | |
| May 12, 2026 | Piper Sandler | $12.00(+20%) | $9.99 | TheFly | |
| Oct 27, 2025 | H.C. Wainwright | Matthew Caufield | $56.00(+81%) | $30.87 | StreetInsider |
| Oct 10, 2025 | Piper Sandler | $67.00(+45%) | $46.25 | TheFly | |
| Apr 14, 2025 | Piper Sandler | Biren Amin | $51.00(+119%) | $23.24 | TheFly |
| Aug 15, 2024 | Piper Sandler | Joseph Catanzaro | $36.00(+62%) | $22.25 | StreetInsider |
| Aug 15, 2024 | Citigroup | Yigal Nochomovitz | $32.00(+36%) | $23.50 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Citigroup | maintain | Buy | Nov 5, 2026 |
| HC Wainwright & Co. | maintain | Buy | Oct 30, 2026 |
| TD Cowen | maintain | Buy | Oct 29, 2026 |
| TD Cowen | maintain | Buy | Oct 21, 2026 |
| Piper Sandler | maintain | Neutral | Oct 19, 2026 |
| Piper Sandler | maintain | Neutral | Aug 12, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 7, 2026 |
| Citigroup | maintain | Buy | May 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 12, 2026 |
| Piper Sandler | downgrade | Overweight →Neutral | May 12, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 21, 2026 |
| Citigroup | maintain | Buy | Mar 26, 2026 |
| B of A Securities | maintain | Buy | Mar 25, 2026 |
| Raymond James | maintain | Outperform | Oct 20, 2025 |
| Piper Sandler | maintain | Overweight | Oct 10, 2025 |
| Citigroup | maintain | Buy | Aug 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 1, 2025 |
| Citigroup | maintain | Buy | Jul 31, 2025 |
| Raymond James | maintain | Outperform | Jul 31, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jul 28, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 16, 2025 |
| Piper Sandler | maintain | Overweight | Apr 14, 2025 |
| Citigroup | maintain | Buy | Mar 20, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 7, 2024 |
Earnings History
Next report: Mar 23, 2027 · EPS est. $-0.82| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 28, 2026 | $-0.99 | $-0.89 | $3.4M | $4.2M |
| Aug 11, 2026 | $-1.02 | $-1.05 | $5.5M | $2.4M |
| May 11, 2026 | $-1.32 | $-1.10 | $1.9M | $1.8M |
| Mar 24, 2026 | $-1.16 | $-0.91 | $1.6M | $3.1M |
| Nov 5, 2025 | $-0.59 | $-0.67 | $12.5M | $3.1M |
| Jul 30, 2025 | $-0.53 | $-0.58 | $5.0M | $714.3K |
| May 7, 2025 | $-0.53 | $-0.55 | — | $714.3K |
| Mar 19, 2025 | $-0.46 | $-0.42 | — | — |
News
LENZ Therapeutics, Inc. ( LENZ ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants Daniel Chevallard - CFO, Principal Financial & Accounting Officer Evert Schimmelpennink - President, CEO, Secretary & Director Shawn Olsson - Chief Commercial Officer Conference Call Participants Stacy Ku - TD Cowen, Research Division Alyssa Larios - Leerink Partners LLC, Research Division Yigal Nochomovitz - Citigroup Inc. Exchange Research Lachlan Hanbury-Brown - William Blair & Company L.L…
LENZ Therapeutics NASDAQ: LENZ reported third-quarter 2026 product revenue of $2.6 million, up 50% sequentially, as prescriptions for its presbyopia eye drop VIZZ increased following the expansion of national advertising and the launch of a telehealth channel.
LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to a loss of $0.59 per share a year ago.
Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increases
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results.
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
LENZ Therapeutics (NASDAQ: LENZ - Get Free Report) and Eloxx Pharmaceuticals (NASDAQ: ELOX - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends. Profitability This table compares LENZ Therapeutics and
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
LENZ Therapeutics is rated a 'Strong Buy' with a fair value estimate of $21.3, reflecting ~266% upside from current levels. I model peak US Vizz sales at $375M, using a 5-pack annualized purchase rate and 30% market share, with conservative international assumptions. LENZ's speculative nature persists due to single-product risk, high SG&A, uninsured status, and rising competition; position sizing remains limited.
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ).
Bank of America Corp DE lifted its stake in LENZ Therapeutics, Inc. (NASDAQ: LENZ) by 377.4% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 547,534 shares of the company's stock after purchasing an additional 432,846 shares during the quarter. Bank